Biofrontera (NASDAQ:BFRI) Announces Earnings Results

Biofrontera (NASDAQ:BFRI) issued its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.01, Zacks reports. Biofrontera had a negative net margin of 47.28% and a negative return on equity of 22,164.13%. The firm had revenue of $6.99 million for the quarter, compared to analysts’ expectations of $7.00 million.

Biofrontera Stock Performance

Shares of Biofrontera stock traded down $0.03 during trading on Friday, hitting $0.86. 210,502 shares of the company’s stock were exchanged, compared to its average volume of 234,730. The stock has a market capitalization of $10.03 million, a price-to-earnings ratio of -0.45 and a beta of 0.55. The business has a 50-day simple moving average of $0.98 and a 200-day simple moving average of $0.85. Biofrontera has a 52-week low of $0.54 and a 52-week high of $1.87. The company has a debt-to-equity ratio of 8.99, a quick ratio of 0.75 and a current ratio of 0.96.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. raised its stake in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 976,448 shares of the company’s stock after buying an additional 332,055 shares during the quarter. Biofrontera comprises about 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned about 9.63% of Biofrontera worth $695,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BFRI shares. Benchmark reiterated a “buy” rating on shares of Biofrontera in a report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biofrontera in a research note on Thursday, October 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.75.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.